NEFL and myeloid sarcoma: Another suggested biomarker is serum neurofilament light chain (NfL) levels (23, 24), but it is only useful in verifying PML onset and resolution of the disease (in natalizumab-treated MS patients) as opposed to predicting who may get PML in the future (i.e., before a patient decides to take a PML-linked therapy).